Open Access Open Badges Research

Broadly reactive antibodies specific for Plasmodium falciparum MSP-119 are associated with the protection of naturally exposed children against infection

Arlene E Dent12*, Ann M Moormann3, Christopher T Yohn1, Rhonda J Kimmel1, Peter O Sumba4, John Vulule4, Carole A Long5, David L Narum6, Brendan S Crabb7, James W Kazura1 and Daniel J Tisch18

Author Affiliations

1 Center for Global Health and Diseases, Case Western Reserve University, Cleveland, OH, USA

2 Pediatrics Department, Rainbow Babies and Children’s Hospital, Cleveland, OH, USA

3 Pediatrics Department, University of Massachusetts Medical School, Worcester, MA, USA

4 Kenya Medical Research Institute, Kisumu, Kenya

5 Laboratory of Malaria and Vector Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

6 Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA

7 Burnet Institute of Medical Research, Melbourne, Australia

8 Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH, USA

For all author emails, please log on.

Malaria Journal 2012, 11:287  doi:10.1186/1475-2875-11-287

Published: 21 August 2012



The 19 kDa C-terminal region of Plasmodium falciparum Merozoite Surface Protein-1 is a known target of naturally acquired humoral immunity and a malaria vaccine candidate. MSP-119 has four predominant haplotypes resulting in amino acid changes labelled EKNG, QKNG, QTSR and ETSR. IgG antibodies directed against all four variants have been detected, but it is not known if these variant specific antibodies are associated with haplotype-specific protection from infection.


Blood samples from 201 healthy Kenyan adults and children who participated in a 12-week treatment time-to-infection study were evaluated. Venous blood drawn at baseline (week 0) was examined for functional and serologic antibodies to MSP-119 and MSP-142 variants. MSP-119 haplotypes were detected by a multiplex PCR assay at baseline and weekly throughout the study. Generalized linear models controlling for age, baseline MSP-119 haplotype and parasite density were used to determine the relationship between infecting P. falciparum MSP-119 haplotype and variant-specific antibodies.


A total of 964 infections resulting in 1,533 MSP-119 haplotypes detected were examined. The most common haplotypes were EKNG and QKNG, followed by ETSR and QTSR. Children had higher parasite densities, greater complexity of infection (>1 haplotype), and more frequent changes in haplotypes over time compared to adults. Infecting MSP-119 haplotype at baseline (week 0) had no influence on haplotypes detected over the subsequent 11 weeks among children or adults. Children but not adults with MSP-119 and some MSP-142 variant antibodies detected by serology at baseline had delayed time-to-infection. There was no significant association of variant-specific serology or functional antibodies at baseline with infecting haplotype at baseline or during 11 weeks of follow up among children or adults.


Variant transcending IgG antibodies to MSP-119 are associated with protection from infection in children, but not adults. These data suggest that inclusion of more than one MSP-119 variant may not be required in a malaria blood stage vaccine.

Plasmodium falciparum; Antibodies; Merozoite surface protein; Malaria infection; Children